(2)
Faricimab given at intervals of up to every 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks, potentially reducing the frequency of injections and overall burden of treatment
Nearly half of people were treated with faricimab every 16 weeks during the first year - the first time this level of durability has been achieved in a phase III study of an injectable eye medicine for neovascular age-related macular degeneration
Faricimab is the first investigational bispecific antibody designed for the eye and targets two distinct pathways - via angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) - that drive a number of retinal conditions
Roche mit Augenmittel Faricimab in Studien erfolgreich
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MIDDAY BRIEFING - Unternehmen und Märkte -2-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MIDDAY BRIEFING - Unternehmen und Märkte -3-
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
MacuHealth Hires Professor James Stringham as Chief Scientific Officer
News provided by
Share this article
Share this article
BIRMINGHAM, Mich., Jan. 19, 2021 /PRNewswire/ Professor Stringham brings with him nearly twenty years of experience researching how to improve vision through nutritional supplementation both in healthy eyes (athletes, military personnel such as pilots) and diseased eyes ranging from Age Related Macular Degeneration to glaucoma.
He has worked with both government agencies and private industry.
Dr. Stringham earned doctoral degrees in experimental psychology and neuroscience from the University of New Hampshire in 2003. During postdoctoral appointments at Harvard medical School and the Medical College of Georgia, he conducted research on the effects of the dietary carotenoids lutein, zeaxanthin, and meso-zeaxanthin on age?related macular degeneration, visual performance, and the plasticity of the visual system.